Press releases

Subscribe to our newsletter via email and sms

View reports from

1 April, 2020

Karo Pharma enters the Swiss market with direct presence by acquiring Hygis SA

Karo Pharma AB (Karo) has today acquired Hygis SA (Hygis), a Swiss distributing company with exclusive distribution rights to Karo’s brands MultiGyn and MultiMam. Hygis operations is limited to the distribution of these brands and by the acquisition Karo gains control over the direct sales of its brands. Karo expects to reach an annual net...

Read more
1 April, 2020

Karo Pharma publishes the 2019 annual report

Today, on 1 April 2020, Karo Pharma is publishing its annual report for 2019 on the company’s website, www.karopharma.com. FOR ADDITIONAL INFORMATION, PLEASE CONTACT: Jon Johnsson, CFO, +46 735 078 861, jon.johnsson@karopharma.com ABOUT KARO PHARMA Karo Pharma specialises in the sales and marketing of prescription drugs and over the counter products for everyday healthcare. Karo...

Read more
27 March, 2020

Karo Pharma postpones the Annual General Meeting to 25 May, 2020

The board of directors of Karo Pharma Aktiebolag (”Karo Pharma”) has resolved to postpone the Annual General Meeting to 25 May, 2020. The previously communicated date for the meeting was 29 April 2020. The delay is due to the increased concern of the spread of COVID-19 with the related safety of the participants. A notice...

Read more
2 March, 2020

Karo Pharma completes the acquisition of product portfolio from LEO Pharma

Karo Pharma Aktiebolag (“Karo Pharma”) today announces that the acquisition of the intimate care and dermatology product portfolio from LEO Pharma for 90 MEUR, which was signed and announced by Karo Pharma on 23 December 2019 and approved by relevant competition authorities on 20 February 2020, has been completed.

Read more
19 February, 2020

Year-end report 2019

OCTOBER – DECEMBER · Net sales amounted to MSEK 649.3 (463.3). This corresponds to an increase of 40% for the period. The organic growth during the fourth quarter was -4 %, currency impact 2 % and 42 % refers to the acquisition of Trimb. · Adjusted EBITDA* amounted to MSEK 151.4 (165.4) excluding non-recurring items,...

Read more
4 February, 2020

Termination of Karo agreement with Pfizer

Karo Pharma AB (“Karo”) has been informed by Pfizer Inc. (“Pfizer”) about its decision to terminate the Research Collaboration and License Agreement, which the two companies entered in December 2011. Following the wind-down of this agreement, there will be no active collaboration agreements between the two companies. This information follows Pfizer’s decision to terminate a...

Read more